Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00397228 · ClinicalTrials.gov registry record · Phase 2
ALTROPANE® SPECT Imaging in Patients With Parkinson Disease
A Phase 2 study, sponsored by Molecular NeuroImaging.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT00397228 is a Phase 2 study that has completed, run by Molecular NeuroImaging. The registered enrollment target is 27 participants.
The verdict
NCT00397228, a Phase 2 study, has completed, sponsored by Molecular NeuroImaging.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
After a screening evaluation including baseline clinical laboratory testing, a physical and neurological evaluation, subjects will be asked to undergo an injection of ALTROPANE® followed by up to 60 minutes of serial dynamic imaging. Subjects will undergo a second injection of ALTROPANE® followed by up to 60 minutes of serial dynamic imaging within 2-6 weeks of the injection 1.
Interventions
- DRUG ALTROPANE®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2006-11 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00397228
The ClinicalTrials.gov registry entry for NCT00397228 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Molecular NeuroImaging, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ALTROPANE® is the first listed.
NCT00397228 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00397228 about?
NCT00397228 is a clinical study titled "ALTROPANE® SPECT Imaging in Patients With Parkinson Disease". After a screening evaluation including baseline clinical laboratory testing, a physical and neurological evaluation, subjects will be asked to undergo an injection of ALTROPANE® followed by up to 60 minutes of serial dynamic imaging. Subjects will undergo a second injection of ALTROPANE® followed by...
What is the current status of trial NCT00397228?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2006-11. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00397228?
The interventions under investigation include: ALTROPANE® (DRUG).
Who is sponsoring clinical trial NCT00397228?
This trial is sponsored by Molecular NeuroImaging, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.